We are thrilled to announce a groundbreaking collaboration between Medlior Health Outcomes Research and MORSE Consulting, two leaders in the Canadian pharmaceutical market access landscape. This partnership aims to blend Medlior’s cutting-edge real-world evidence solutions with MORSE Consulting’s unparalleled expertise in payer and HTA strategies, offering our clients an unmatched array of services to navigate the complex world of pharmaceutical market access.
Medlior is a leading independent Canadian research organization specializing in real-world evidence, health technology submissions, and evidence synthesis. Our team’s real-world evidence expertise spans from managing ethics approval and engaging in research agreements with data custodians, to conducting complex data linkages and analyses. With a focus on client-centric project management and delivery, Medlior offers a wide range of HTA and Evidence Synthesis services, including systematic literature reviews, economic evaluations, and medical writing, tailored to meet our clients’ needs in Canada and globally.
MORSE Consulting is a leader in Canadian market access strategy, known for its bespoke solutions and client-centric approach. With a team of professionals boasting extensive experience in payers, HTA, pCPA negotiations, and market access strategy consulting, MORSE Consulting provides unparalleled insights that set it apart from any other consultancy in Canada. Their advice is grounded in authentic and credible communication, and their comprehensive range of services, including pCPA assessment & negotiation simulation and HTA strategic advice, ensures that clients are well-prepared for every stage of their market access journey.
Our first collaborative service, the Advanced Innovative Agreements/Real-World Evidence (RWE) Workshop, empowers pharmaceutical companies to shape successful market access strategies. This workshop addresses the unique challenges posed by innovative therapies like cell and gene therapies, drugs for rare diseases, and precision oncology. By leveraging Medlior’s expertise in real-world evidence and MORSE Consulting’s expertise in reimbursement strategy, we offer a comprehensive and customized approach to meet the specific needs of your product. This workshop is an invaluable resource for pharmaceutical companies at any stage of drug development.
This service is just the beginning. We are actively exploring other avenues to expand our collaboration, aiming to provide even more value to our clients. If you want to learn more about how this collaborative venture can benefit your organization, please contact Tara Cowling at or MORSE Consulting’s Director, Innovative Access Solutions, Sang Mi Lee () for further information.
